MS

MCKESSON

Empowering Healthcare

MALARKEY CAPITAL MANAGEMENT

SEPTEMBER 30TH, 2016

Overview

Headquarters: San Francisco, CA

Medical Distribution Industry

Market Cap: 38 Billion


Today's Price: \$166.43

Return on Equity & Return on Capital: >15%

Price/Earnings Ratio: 17x

Price/Owners Earnings Ratio: 14.5x

PEG Ratio: 1.13



History

1833 - Founded by John McKesson in New York City as a drug wholesaler

1855 - Became one of the first wholesale firms to manufacture drugs

1900s - Became the largest wholesaler of pharmaceutical drugs after buying several competing wholesalers

1960s - Became Foremost-McKesson Inc. after merging with the Foremost Dairies

1990s – Focus shifts to health care specifically and acquires General Medical, the largest distributor of medical-surgical supplies.

1993 - Founded Acumax, a barcode warehouse management solution.

2010 - Acquired US Oncology, becoming the second-largest specialty company

2013 - Announced CommonWell Health Alliance, an effort among health IT suppliers to support universal access to health care data

2014 - Acquired Celesio, which made McKesson the 11th largest company on the Fortune 500







MS

Acquisitions

- **2016**
 - ▶ Biologics, Inc. (Services to providers and patients, solutions to manufacturers and payers)
 - ► TBD Rexall Health (470 Canadian Pharmacies)
- **>** 2014
 - ► Celesio (International Distribution)
- **>** 2013
 - ▶ PSS World Medical, Inc. (Medical-Surgical Distribution)





Business





What Do We Do?

- ► Global pharmaceutical distribution services and information technology
- ➤ Deliver a comprehensive offering of pharmaceuticals and medical supplies as well as technological services
- ➤ Work with payers, healthcare providers, pharmacies, pharmaceutical companies and others across the healthcare industry




Business Segments

▶ Distribution Solutions

- ▶ Branded and generic pharmaceutical drugs
- ► Medical and surgical supply equipment
- ► Inventory Management

Technology Solutions

- ► Hospital/Clinical services
- Patient Care
- ► Financial
- ► Supply Chain Management



■ Distribution Solutions

■ Technology Solutions





Distribution Solutions Customers

Retail National Accounts

Independent Retail
Pharmacies

Institutional Healthcare Providers


Central Fill™
Redistribution Centers
McKesson SynerGx®

HealthMart®
McKesson OneStop
Generics®

Fulfill-Rx
Asset Management



How Do We Make Money? (Distribution Solutions)



Technology Solutions

MC

McKesson Health Solutions

Connected Care and Analytics

Imaging and Workflow Solutions

Business Performance Services

Enterprise Information Solutions

Cost Management and Compliance

Streamline Communication

Advanced Screening Solutions

Revenue Cycle Management

Workflow Management

Technology Solutions




Technology Solutions Merger

- ▶ June 28, 2016 McKesson and Change HealthCare announced a merger agreement
 - ▶ 70% of McKesson Technology Solutions
 - ▶ 100% of Change HealthCare
- ▶ New company expected to produce \$4 Billion in annual revenues
 - ► McKesson owns 70%
 - ► Change HealthCare owns 30%

How Do We Make Money? (Technology Solutions)





One time fees vs Re-occurring fees





Economic Moat


- ► Operate in a Duopoly
- ► Market Share
 - ► McKesson, Cardinal Health, and AmerisourceBergen have 90% market share
- ► Size and Scale
- ▶ Distribution Network
 - ► Largest percentage of small pharmacies in North America



MS

Risk Factors

- ► Changes in United States and Canadian HealthCare System
 - ► Reforms
 - ► Government Caps on Markup Price
- ► Pricing Transparency
- ► Industry Consolidation



Qualitative Review

IVI	

What type of business is this: commodity or sustained competitive advantage?	Sustained Competitive Advantage
Can you easily explain what the business does?	Yes
Is it heavily unionized?	There is a union presence
Does it require heavy capital infusion?	No
Does it require lots of R&D?	No
Can inventory become obsolete?	Yes
Are there chronic "one-time" write-offs?	No
Is the company able to raise its prices to offset inflation?	No
Will the company be able to sell more in the future?	Yes
If I gave you \$1 billion could you develop a competitor?	No


Interpretation of Financial Statements

IVI	M	C
-----	---	---

<u>TTM</u>	<u>Value</u>	<u>Threshold</u>	<u>Ruling</u>
Gross Profit Margin	5.98%	≥ 20%	Fail
SGA % of GP	63.73%	≤ 80%	Pass
R&D % of GP	3.43%	≤ 10%	Pass
Depreciation % of GP	2.46%	≤ 10%	Pass
Interest % of OP	9.96%	≤ 15%	Pass
Net Profit Margin	1.18%	≥ 10%	Fail
Current Ratio	1.10	≥ 1	Pass
Obligation Ratio	1.41 years	< 5 years	Pass
Adj. Debt to Shareholder Equity	0.65	< 0.8	Pass
Return on Equity	26.68%	≥ 15%	Pass
Return on Capital	19.88%	≥ 15%	Pass
Dividend Payout Ratio	11%	≤ 60%	Pass
Preferred Stock	None	None	Pass
CAPEX/Net Income	29%	≤ 25 %	Fail
Net Earning Trend	Increasing	Increasing	Pass
Retained Earnings Trend	Increasing	Increasing	Pass


Historical Trend Analysis


Metric	Ruling
Sales per Share	Increasing
Cash flows per Share	Increasing
Earnings per Share	Increasing
Dividends Declared per Share	Increasing
Book Value per Share	Increasing
Revenues	Increasing
Gross Profit Margin	Increasing
Operating Profit Margin	Increasing
Net Profit	Increasing
Net Profit Margin	Increasing
Working Capital	Increasing
Return on Total Capital	Increasing
Return on Shareholder's Equity	Increasing
Common Shares Outstanding	Decreasing
Long Term Debt	Increasing
LTD Payable in 5 years	Yes
All Dividends to Net Profit under 60%	Yes

















Yield to Maturity

Mckesson Corp New 2.7%

Mckesson Corp New 3.796%

Per-Se Tech Cv 3.25%

Mckesson 2.85%



102.1

103.7

108.9

2,700

2.850

3.796

3.250

Fixed

Fixed

Fixed

Fixed

No

No

No

No

No

No

No

No

2.33

2.24

2.48

12/15/2022

03/15/2023

03/15/2024

06/30/2024


400.0


400.0


125.0

1,100.0














2006-12-31 2007-03-31 2007-03-31 2007-09-30 2007-09-30 2007-12-31 2008-09-30 2008-09-30 2008-09-30 2012-09-30 2012-09-30 2012-09-30 2012-09-30 2012-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2013-09-30 2014-09-30 2015-09-30











Price/Free Cashflow











Value Bands

Metric	Multiple	Rank
Price/Sales	0.2	60%
Price/Owner's Earnings	8.9	19%
Price/Earnings – Cash	15.2	45%
Price/Earnings	17.2	39%
Price/Book	4.0	72%
Price/Cash Flow	7.5	15%
Price/Free Cash Flow	8.7	10%
EV/Revenue	0.2	64%
ev/ebitda	9.1	49%
EV/EBIT	11.3	50%





	Ticker	Price / Sales
D	MCK	0.2
Þ	WMT	0.5
Þ	BBBY	0.6
Þ	CHRW	0.8
D.	PII	1.1
D.	CMI	1.2
D.	AIG	1.4
Þ	BRK.B	1.7
D	IBM	1.9
D	NSRGY	2.7
Þ	UNP	4.0
D	QCOM	4.2
Þ	ORCL	4.6
b	MSFT	5.4

	Ticker	▲ Price / Earnings
D:	BRK.B	- 5
D:	BBBY	8.5
D.	IBM	12.8
D.	PII	13.1
D	WMT	15.6
Þ	MCK	16.3
D	CMI	16.4
D:	NSRGY	17.5
D:	QCOM	18.5
D:	UNP	18.5
D	ORCL	19.0
D	CHRW	19.1
D	MSFT	27.6
D	AIG	*:

	Ticker	▲ P/E Adjusted		
Ď.	BRK.B			
Þ	BBBY	9.9		
D	PII	13.8		
D	IBM	16.2		
D	CMI	16.9		
٥	QCOM	17.2		
Þ	ORCL	17.3		
Þ	MCK	17.8		
D	NSRGY	18.4		
Þ	WMT	18.8		
Ď.	CHRW	20.5		
Ď.	UNP	22.0		
Ď.	MSFT	23.9		
D	AIG			

	Ticker	Price / Book	
þ	AIG	0.7	
b	BRK,B	1.4	
þ	BBBY	2.6	
b	WMT	2.9	
b	CMI	3.0	
b	QCOM	3.0	
b	ORCL	3.4	
b	UNP	3.9	
b	NSRGY	4.0	
b	MCK	4.1	
þ	PII	5.2	
b	MSFT	6.3	
b	CHRW	7.9	
b	IBM	9.5	

	Ticker	▲ Price / FCF
Þ	MCK	8.7
Þ	BBBY	9.3
Þ	IBM	10.6
Þ	WMT	10.8
Þ	PII	11.9
Þ	ORCL	13.7
Þ	CMI	14.1
Þ	QCOM	14.9
Þ	CHRW	15.6
Þ	MSFT	18.6
\triangleright	BRK.B	20.5
Þ	AIG	24.3
Þ	NSRGY	25.5
Þ	UNP	26.4

	Ticker	▲ 52-w	k Range
D	BBBY	\$41.15	\$61.49
D	PII	\$67.80	\$124.39
D	MCK	\$148.29	\$202.20
Þ	CHRW	\$59.71	\$76.10
Þ	AIG	\$48.41	\$64.31
Þ	ORCL	\$33.13	\$42.00
D	NSRGY	\$68.00	\$83.25
D	BRK.B	\$123.55	\$151.05
Þ	IBM	\$116.90	\$164.95
Þ	WMT	\$56.30	\$75.19
Þ	CMI	\$79.88	\$127.64
Þ	UNP	\$67.06	\$98.28
Þ	MSFT	\$43.05	\$58.70
Þ	QCOM	\$42.24	\$64.00



Historical Intra-Evaluations

	Ticker	▲ 5-Year	Price / Sal	es Range
Þ	NSRGY			
Þ	BBBY	0.6		1.9
Þ	PII	1.0		3.1
Þ	CHRW	0.6		1.3
Þ	MCK	0.2	1	0.3
Þ	WMT	0.4	1	0.6
Þ	QCOM	2.8		7.2
Þ	CMI	0.8	-	1.7
Þ	IBM	1.4		2.4
Þ	ORCL	3.6		5.4
Þ	BRK.B	1.2	-	2.0
Þ	UNP	2.1		4.9
Þ	AIG	0.3		1.4
Þ	MSFT	2.9		5.5

	Ticker	▲ 5-Year I	Price / Earning	s Rang
	NSRGY			
	BBBY	8.2		18.2
	MCK	13.2	1	38.4
	PII	9.9		30.6
×	CHRW	14.0	-	29.7
	QCOM	12.4		24.9
	WMT	11.6		18.9
	UNP	11.9	-	24.0
	IBM	8.1		16.0
	CMI	8.3	-	20.3
	ORCL	13.3	-	20.3
	MSFT	8.8		39.5
	AIG	1.8		1-
	BRK.B	13.4		1-

	Ticker	▲ 5-Year P	rice / Boo	k Rang
>	NSRGY			
>	BBBY	2.6		5.0
	PII	4.8		17.6
	IBM	8.0		14.5
×	ORCL	2.9		4.3
×	WMT	2.3		3.8
	CHRW	5.7	-	11.2
	CMI	1.9	-	4.5
	MCK	2.4	- 1	6.8
	BRK.B	1.1	-	1.6
	QCOM	2.0	-	4.1
	UNP	2.1	- 1	5,1
	AIG	0.4		0.8
	MSFT	3.1		6.3

	Ticker	▲ 5-Year P	rice / Cash	Flow Ra
×	NSRGY			
Σ.	BBBY	6.1		14.9
×	WMT	6.8		12.3
Σ.	PII	6.7		23.4
×	CHRW	13.4		30.8
>	MCK	6.0	1	21.7
ä,	QCOM	11.3	1	20.7
	IBM	6.5	-	12.8
	CMI	7.2		15.3
	BRK.B	8.3		14.1
×	UNP	6.9		16,6
×	ORCL	9.6	-	14.3
Σ	AIG	5.7	- 1	-
×	MSFT	7.1		16.1

	Ticker	A 5	Year Price R	ange
Þ	BBBY	\$41.15		\$80.82
Þ	PII	\$46.83	1	\$159.33
Þ	IBM	\$116.90	-	\$215.90
Þ	CMI	\$79.53		\$161.03
Þ	WMT	\$51.29		\$90.97
Þ	QCOM	\$42.24	- 1	\$81.97
Þ	MCK	\$66.61	1	\$243.61
Þ	UNP	\$38.87	- 1	\$124.52
Þ	ORCL	\$24.91	-	\$46.71
Þ	CHRW	\$50.21	-	\$77.49
Þ	AIG	\$19.18		\$64.93
Þ	NSRGY	\$53.48		\$83.25
Þ	BRK.B	\$69.07		\$152.94
Þ	MSFT	\$24.26		\$58.70



DuPont Historical MCK


MCK	Total Asset Turnover	Net Profit Margin	Financial Leverage Multiplier	Return on Equity
TTM	3.43	1.15	6.26	24.88
2016	3.46	1.18	6.34	26.68
2015	3.39	0.82	6.73	17.87
2014	3.18	0.92	6.07	16.20
2013	3.60	1.09	4.92	19.25



DuPont Competitors (TTM)

	Net Profit Margin	Total Asset Turnover	Financial Leverage Multiplier	Return on Equity
MCK	1.15%	3.43	6.26	24.88
ABC*	1.14%	4.82	16.98	93.30
CAH	1.17%	3.73	5.21	22.79

	MCK	САН	ABC
Market Cap (mil)	37,435	24,895	17,877
Revenue (mil)	193,071	121,546	144,759
Price/Earnings	17.26	18.09	11.29
Price/Sales	0.20	0.22	0.13
Price/Book	4.05	3.84	9.52
EV/EBIT	11.27	11.62	11.30
ROA	3.95	4.38	5.49
ROE	24.88	21.79	108.75
Operating Margin	1.86	2.02	1.27
Net Margin	1.15	1.17	1.14



10 Year

	3/07	3/08	3/09	3/10	3/11	3/12	3/13	3/14	3/15	3/16	EPSttm	Years	HGROWTH	STAEGR [®]
EPS (\$)	3.150	3.320	2.950	4.620	4.570	5.590	5,590	5.410	6.270	9.700	\$9.620	10	11.58%	87.38%
SPS (\$)	312.838	352.200	389.406	401. <mark>1</mark> 14	444.778	522.272	539.449	595.7 <mark>1</mark> 0	771.746	848.373		10	11.28%	95.20%



10 Year - Expected Rate of Return

	Price	EPSttm	P/E Ratio	HGrowth	Payout	STRET®
Default	164.42	\$9.620	24.27	11.58%	13.6%	14.04%
Safety	164.42	\$9.620	14.46	9.13%	2.9%	6.31%

Cut P/E by 40% Cut Growth rate by 20% Cut Payout Ratio by 78%



6 Year

	3/07	3/08	3/09	3/10	3/11	3/12	3/13	3/14	3/15	3/16	EPSttm	Years	HGROWTH	STAEGR [®]	
EPS (\$)	3.150	3.320	2.950	4.620	4.570	5.590	5.590	5.410	6.270	9.700	\$9.620	6	11.92%	88.63%	dd
SPS (\$)	312.838	352.200	389.406	401.114	444.778	522.272	539.449	595.710	771.746	848.373		6	13.73%	95.76%	dd

6 Year

	Price	EPSttm	P/E Ratio	HGrowth	Payout	STRET [®]
Default	164.42	\$9.620	24.27	11.92%	13.6%	14.37%
Safety	164.42	\$9.620	14.46	9.82%	2.9%	6.91%

Cut P/E by 40% Cut Growth rate by 21% Cut Payout Ratio by 78%

3 Year

	3/07	3/08	3/09	3/10	3/11	3/12	3/13	3/14	3/15	3/16	EPSttm	Years	HGROWTH	STAEGR [®]	
EPS (\$)	3.150	3.320	2.950	4.620	4.570	5.590	5.590	5.410	6.270	9.700	\$9.620	3	33.90%	94.29%	Jil
SPS (\$)	312.838	352.200	389.406	401.114	444.778	522.272	539.449	595.710	771.746	848.373		3	19.34%	97.06%	11

MS

3 Year

	Price	EPSttm	P/E Ratio	HGrowth	Payout	STRET [®]
Default	164.42	\$9.620	24.27	33.90%	13.6%	36.03%
Safety	164.42	\$9.620	14.46	14.79%	2.9%	11.31%

Cut P/E by 40% Cut Growth rate by 56% Cut Payout Ratio by 78%

CI – 10 YR Kill It Scenario


	Price	EPSttm	P/E Ratio	HGrowth	Payout	STRET®
Default	164.42	\$9.620	24.27	11.58%	13.6%	14.04%
Safety	164.42	\$9.620	14.46	9.13%	2.9%	6.31%
Saved 2016-10-01	164.42	\$9.620	14.46	6.00%	2.9%	3.65%

Keep P/E at 14.46 Cut Growth rate by 56% Cut Payout Ratio by 78%

CI – 10 YR Kill It Again

	Price	EPSttm	P/E Ratio	HGrowth	Payout	STRET [®]
Default	164.42	\$9.620	24.27	11.58%	13.6%	14.04%
Safety	164.42	\$9.620	14.46	9.13%	2.9%	6.31%
Saved 2016-10-01	164.42	\$9.620	11.50	4.00%	2.9%	0.14%

Cut P/E by 53% Cut Growth rate by 65% Cut Payout Ratio by 78%





DCF - Base Case

Earnings Per Share @ :	\$ 10.22	
Growth Rate In the Next @:	10 Years: 13.5	%
Terminal Growth Rate 🕢 :	4	%
ears of Terminal Growth 🕢 :	10	
Discount Rate @ :	12	%
Business Predictability @:	***	17
Savo Da	rameters	

Fair Value @:	\$ 189.47	
Tangible Book Value	3 : \$ -22.25	
	Add to Fair Value	
Growth Value @ :	\$ 110.04	
Terminal Value 🕢 :	\$ 79.43	
Stock Price:	\$ 164.42	
Margin Of Safety:	13%	



DCF - Bull Case

Growth Rate In the Next 🕢 :	10 Years:	15 %
Terminal Growth Rate 🕢 :	4	%
Years of Terminal Growth 🕢 :	10	
Discount Rate 🕢 :	10	%
Business Predictability 🕢 :	***	

Fair Value @:		\$ 295.72			
Tangil	ble Book Value 🕢 :	\$ -22.25			
		Add to Fair Value			
Growt	h Value 🕢 :	\$ 155.52			
Termi	nal Value 🕢 :	\$ 140.2			
Stock	Price:	\$ 164.42			
Margi	n Of Safety;	44%			




DCF - Bear Case

Earnings Per Share @:	\$ 12.08	
Growth Rate In the Next 🕢 :	10 Years: 6.	30 %
Terminal Growth Rate 🕢 :	4	%
Years of Terminal Growth @ :	10	
Discount Rate @:	10	%
Business Predictability @:	***	T TO
Save Par	rameters	

Fair	Value @:	\$ 164.41
Tangil	ole Book Value 🕢 :	\$ -22.25
		Add to Fair Value
Growt	h Value 🕢 :	\$ 100.56
Termi	nal Value 🕢 :	\$ 63.84
Stock	Price:	\$ 164.42
Margi	n Of Safety:	0%

Valuation





	P/S	P/OE	P/E	P/E-\$	P/B	P/CFO	P/FCF
Current Multiple	0.20	9.02	17.3	15.1	4.07	7.6	8.8
20% Rank Multiple Per Share Figures	0.16 x 834.9	9.01 x 18.5	14.6 x 9.7	12.7 17.9	2.4 x 40.9	7.7 x 21.9	9.2 x 19.1
Prices	\$133.58	\$166.68	\$141.62	\$148.66	\$98.14	\$168.63	\$175.72

Buy Price


Buy Price = \$147.57

MS

Conclusion


- ► Monopoly like business
- Sound financials and growth record
- ► HealthCare Industry can be unpredictable but McKesson will continue to distribute drugs and equipment in the future
- Value Gap


Recommendation: Limit Order at \$148 or wait until better premiums appear





Appendix





MCKESSON

McKesson's Executive Committee



Diverse and Experienced Leadership

John H. Hammergren Chief Executive Officer, President & Chairman 20 years

Paul Julian EVP & Group President 20 years Pat Blake President EVP & Group President 20 years

James Beer Chief Financial Officer 3 years

Kathy McElligott Chief Information Officer/ Chief Technology Officer 1 year Bansi Nagji EVP, Corporate Strategy & Business Development 1 year Jorge Figueredo
EVP, Corporate Human Resources
& Administration
8 years

Lori Schechter EVP, General Counsel & Chief Compliance Officer 4 years

McKesson's Executive Committee

John H. Hammergren

- ▶ Chief Executive Officer, President, and Chairman of the Board
 - ▶ 20 year career at McKesson
 - ▶ 15 years as the CEO
- ▶ Under his management, revenues have more than quadrupled
- Named "Top 100 CEOs in the World" by *Harvard Business Review*



McKesson's Executive Committee

James Beer

- ► Executive Vice President and Chief Financial Officer
 - ▶ 3 years as the CFO
- ➤ Served as the Executive Vice President and CFO of Symantec
 - ► Managed the worldwide finance organization
- ➤ Served in several management positions at American Airlines for over 15 years

